Piper Sandler analyst Yasmeen Rahimi continues to have "high conviction" that Intercept will receive FDA approval of obeticholic acid, or OCA, for patients with pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis, or NASH by the PDUFA date on June 22, arguing that the re-analysis dataset "clearly highlights the benefits of the drug and manageable safety profile." The firm maintains an Overweight rating and $49 price target on Intercept shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ICPT:
- FDA accepts Intercept NDA for OCA to treat NASH pre-cirrhotic liver fibrosis
- Intercept sees FY22 net sales of $343M, up 10% y/y
- Intercept announcse efficacy, safety data from Phase 3 REGENERATE study
- Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023
- Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH
